---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-053131"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:26:24.788757+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cogent Biosciences reports Q4/FY2025 results; advances bezuclastinib NDAs in SM and GIST

## Summary
- SUMMIT NDA for bezuclastinib in NonAdvSM submitted Dec 2025; APEX NDA for AdvSM on track for 1H 2026.
- PEAK NDA for bezuclastinib in 2L GIST initiated under RTOR and BTD; completion expected April 2026.
- Cash, equivalents and marketable securities $900.8M as of Dec 31, 2025, sufficient into 2028.
- Net loss $102.5M in Q4 2025, $328.9M full year, vs $67.9M and $255.9M in prior year periods.
- Inducement grants: options to purchase 59,300 shares and 47,000 RSUs to 12 new employees.

## SEC filing metadata
- accession: 0001193125-26-053131
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000119312526053131/0001193125-26-053131-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000119312526053131/cogt-20260217.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-053131
- JSON: https://secwatch.observer/filing/0001193125-26-053131.json
- Plain text: https://secwatch.observer/filing/0001193125-26-053131.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.